Caribou Biosciences

Caribou was co-founded by Jennifer Doudna, who with Emmanuelle Charpentier won the 2020 Nobel Prize for discovering the CRISPR-Cas9 system. The University of California, Berkeley owns foundational CRISPR patents that Caribou exclusively licensed for certain commercial fields. A rival CRISPR patent portfolio is held by the Broad Institute of MIT and Harvard, licensed primarily to Editas Medicine. Years of patent interference proceedings resulted in a split decision: the Broad retains key eukaryotic editing patents in the US, while UC and its licensees control rights in many European and Asian jurisdictions. Caribou navigates this by using its own intellectual property and CRISPR enzyme variants to engineer its pipeline.

ChRDNA stands for CRISPR hybrid RNA-DNA and represents Caribou's next-generation editing platform. The company's chRDNA guides use a combination of RNA and DNA bases to direct the Cas12a or Cas9 enzyme to the target genomic site. Caribou reports that this approach significantly increases editing fidelity and reduces off-target mutations compared to traditional single-guide RNA systems, which is critical for therapeutic applications where unintended edits could cause cellular dysfunction or oncogenesis.

Allogeneic means the starting cell material comes from healthy donors rather than the patient themselves. Autologous cell therapies, like most approved CAR-T treatments, require extracting a patient's own T cells, engineering them, and reinfusing them — a process that can take weeks and is logistically fragile. Caribou edits donor-derived T cells or NK cells to create 'off-the-shelf' products that can be manufactured in advance, stored, and infused when needed, potentially reducing cost, wait time, and manufacturing failure risk.

Yes. Caribou has historically earned licensing and royalty revenue by granting commercial rights to its CRISPR intellectual property to companies in fields outside human therapeutics, most notably a long-standing partnership with DuPont (now part of Corteva Agriscience) for agricultural applications. The company earns milestone fees and royalties from these agreements. However, the business has shifted focus almost entirely to advancing its internal oncology pipeline, and licensing fees are a diminishing portion of the overall corporate activity.

Rachel Haurwitz has served as President and CEO since the company's founding and holds a PhD in molecular biology from the University of California, Berkeley, where she studied in Jennifer Doudna's laboratory. The scientific leadership team includes prominent immunologist and cell therapy veterans who manage preclinical research and clinical trial execution for the allogeneic CAR-T assets. The board of directors includes Doudna, who remains actively engaged as a scientific founder.

Caribou is a clinical-stage biopharmaceutical company, not a family office or investment vehicle. It is a publicly traded corporation listed on Nasdaq under the ticker CRBU. The firm's primary activity is drug development and clinical trial execution; it does not manage external capital in the manner of a venture firm or family office.

Caribou has not disclosed a major pharmaceutical co-development partner for its lead oncology programs as of mid-2025. The company retains full worldwide commercial rights to its clinical-stage assets, a deliberate strategy to capture more long-term value. Its primary external partnership has been in agricultural biotechnology through a collaboration that predates the strategic pivot to oncology.